drugset

drugset / Trial / NCT05088876

Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control

NCT05088876 ↗

Phase 4 Terminated 7 enrolled Insel Gruppe AG, University Hospital Bern Swiss National Science Foundation · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

Blinded withdrawal of regular co-medication with paracetamol in chronic pain patients under strong opioids on pain control.

Timeline

Start: 2024-08-28
Primary completion: 2026-03-05
Completion: 2026-03-05

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment difficulties”

Publications

Kotoula C, Wertli MM, Streitberger K, Rothschild SI, Limacher A, Hammann F, Krahenbuhl S, Haschke M, Liakoni E. Efficacy of paracetamol added to WHO step III opioids in chronic pain control: study protocol for a randomised, double-blind, placebo-controlled, non-inferiority, multicentre study in Switzerland. BMJ Open. 2025 Dec 31;15(12):e107360. doi: 10.1136/bmjopen-2025-107360.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Acetaminophen	Small molecule	1.5 g	—

Indications

No indication recorded.